TORONTO, Aug. 3 /CNW/ - Amorfix Life Sciences Ltd. (TSXV: AMF), an
emerging Canadian theranostics company, announced today that it has entered
into a research and investment agreement with Biogen Idec (NASDAQ: BIIB) of
Cambridge, Massachusetts, which includes an option to license the exclusive
worldwide rights to Amorfix's technology to develop and commercialize
therapeutic products directed against the neurodegenerative disease
Amyotrophic Lateral Sclerosis (ALS). Amorfix will conduct a planned research
program with operational support and investment from Biogen Idec.
